

272

DESCRIPTION OF TIGECYCLINE USE IN  
MULTIDRUG-RESISTANT *ACINETOBACTER*  
*BAUMANNII* PNEUMONIA (A1), Rebecca Keel,  
Kimberly Leuthner. University Medical Center of  
Southern Nevada, Las Vegas, NV

(rebecca.moos@umcsn.com) IRB approval received.

Tigecycline has shown in-vitro effects against *Acinetobacter baumannii* (ACB), but there is limited published clinical experience with its use in multidrug-resistant (MDR) ACB pneumonias. This study evaluated 66 patients with positive MDR ACB respiratory cultures treated with tigecycline. Patients were included if they had suspected or likely pneumonia caused by MDR ACB. The use of concurrent colistin and other antibiotics which had no activity or were resistant to ACB was allowed. Patients were excluded if they were colonized with MDR ACB or received less than 48 hours of therapy with tigecycline. Data was collected retrospectively by reviewing electronic and paper medical records. Descriptive statistics, Fischer exact test, and student t-test were utilized as appropriate for data analysis. A p value of 0.05 or less was considered to be statistically significant. Full results will be discussed.